Differential scanning calorimetry is still a mainstay of drug-polymer miscibility analysis. But now a new microscopy-based imaging method – thermal analysis by structural characterization – has been demonstrated to save time, improve sensitivity, and significantly reduce the amount of material required for drug-polymer miscibility analysis.READ MORE
What happens when you transiently turn "off" the gene that encodes ACE2, the protein that is required for SARS-CoV-2 to enter and infect cells? This is what Jamie Hackett and colleagues are currently exploring in animal models, to determine whether epigenetic silencing could be a treatment approach for COVID-19 in humans.READ MORE
Light and medicine have a long and intertwined past. Most civilizations throughout history appear to have understood that there was a connection between sunlight and good health. Here, we take a closer look at photopharmacology and explore how light can be used to control the activity of PROteolysis-TArgeting Chimeras (PROTACs).READ MORE
Researchers recently reported the development of a novel cancer vaccine. The vaccine is designed to target malignancies that express the transcription factor Wilms' tumor 1 (WT1) – a well characterized and highly immunogenic tumor‐associated antigen. Technology Networks had the pleasure of speaking with the project’s lead researcher, Associate Professor Kristen Radford to learn more about the CLEC9A-WT1 vaccine.READ MORE
In the final part of our exclusive interview series with Blue Brain Project Founder and Director Professor Henry Markram, we discuss the goals that he has strived towards over the last 15 years – simulating the mouse, and eventually human, brain. We discuss the Blue Brain Project’s achievements and setbacks and Markram explains what he feels are the Project’s most surprising findings. Finally, we look towards the future – when will we have simulated the human brain?
In an exclusive interview, Technology Networks spoke with Felix Breden, scientific manager at iReceptor Plus, to learn more about the iReceptor Plus Gateway – a repertoire of almost 200 million T and B cell receptor sequences from COVID-19 patients.READ MORE
David A. Drew, of Massachusetts General Hospital and Harvard Medical School, explains, during the virtual COVID-19 and cancer meeting, how smartphone applications are able to facilitate the collection of self-reported data at scale. He discusses how data collected using the COVID-19 Symptom Study app has helped investigate COVID-19’s impact on racial and ethnic minority communities, and those living with cancer.
In the second of our exclusive three-part interview series with Blue Brain Project Founder and Director Professor Henry Markram, we discuss how brain simulations can benefit neuroscience.